



# Second Quarter Results Fiscal Year 2016

May 5, 2016

## Forward-Looking Statements

- These materials include forward-looking statements and it's possible that actual results could differ from our expectations. Factors that could cause such differences appear in our second quarter earnings release and in our recent SEC filings.

## Non-GAAP Financial Measures

- These materials also include Non-GAAP financial measures. A reconciliation to the comparable GAAP measures can be found herein, or in our earnings release and the financial schedules attached thereto.
- **A copy of the press release, including the financial schedules, is posted on the "Investors" section of the BD.com website.**

## Non-GAAP Financial Measures

- Certain financial information excludes the impact of the following items:
  1. Foreign currency translation.
  2. All adjustments to current and prior year as noted on the "Adjustment Reconciliation" schedules in the appendix of this presentation, including deferred revenue adjustments associated with the write-down of CareFusion's deferred revenue balance to reflect a fair value measurement as of the acquisition date. The deferred revenue adjustment represents the amortization of this write-down which primarily relates to software maintenance contracts. Revenue for these contracts is typically deferred and recognized over the term of the contracts



FXN = Estimated foreign exchange-neutral currency growth. \$ = Dollars in millions except per share data.

Comparable FXN = Estimated foreign exchange-neutral currency growth including BD and CareFusion in the current and prior year periods.

Note: All figures on accompanying slides are rounded. Totals may not add due to rounding. Percentages are based on un-rounded figures.

# Executive Overview

**Vincent A. Forlenza**

Chairman, CEO and President



# Q2 FY 2016 Business Highlights

- ◆ Solid Q2 performance
- ◆ Results continue to demonstrate the breadth and diversity of portfolio
- ◆ Great traction as we mark the one-year anniversary of CareFusion close
- ◆ Portfolio review complete with Respiratory joint venture announcement and sale of Spine business
- ◆ Maintain currency-neutral revenue guidance
- ◆ Raise adjusted EPS guidance

# Q2 FY 2016 Financial Highlights

As Adjusted	Second Quarter				Year-to-Date			
	\$	Growth %	FXN Growth%	Comparable FXN Growth%	\$	Growth %	FXN Growth%	Comparable FXN Growth%
Revenues	\$3,071	49.7%	55.2%	5.3%	\$6,063	47.8%	54.5%	3.5%
EPS	\$2.18	35.4%	44.7%	N/A	\$4.13	31.5%	44.9%	N/A

- ◆ Second quarter revenue growth of 5.3% FXN
- ◆ Strong second quarter EPS of \$2.18

# Financial Update

**Christopher Reidy**

Chief Financial Officer and  
Executive Vice President of Administration



# FY 2016 Adjusted Revenues by Segment

	Second Quarter				Year-to-Date			
As Adjusted	\$	Growth %	FXN Growth%	Comparable FXN Growth%	\$	Growth %	FXN Growth%	Comparable FXN Growth%
<b>Total Revenues</b>	<b>\$3,071</b>	<b>49.7%</b>	<b>55.2%</b>	<b>5.3%</b>	<b>\$6,063</b>	<b>47.8%</b>	<b>54.5%</b>	<b>3.5%</b>
Medical	2,135	93.1%	99.5%	6.1%	4,194	92.6%	100.5%	4.0%
Life Sciences	936	(1.0%)	3.4%	3.4%	1,869	(2.9%)	2.5%	2.5%

# FY 2016 Adjusted U.S. and International Revenues

	Second Quarter				Year-to-Date			
As Adjusted	\$	Growth %	FXN Growth%	Comparable FXN Growth%	\$	Growth %	FXN Growth%	Comparable FXN Growth%
<b>U.S.</b>	<b>\$1,722</b>	<b>99.6%</b>	<b>99.6%</b>	<b>5.7%</b>	<b>\$3,419</b>	<b>95.5%</b>	<b>96.1%</b>	<b>3.6%</b>
Medical	1,281	186.6%	186.6%	5.5%	2,553	181.2%	182.3%	3.7%
Life Sciences	441	6.1%	6.1%	6.1%	866	3.2%	3.2%	3.2%
<b>International</b>	<b>\$1,349</b>	<b>13.5%</b>	<b>23.0%</b>	<b>4.8%</b>	<b>\$2,644</b>	<b>12.1%</b>	<b>23.8%</b>	<b>3.5%</b>
Medical	853	29.6%	40.4%	6.9%	1,641	28.9%	42.3%	4.4%
Life Sciences	495	(6.5%)	1.4%	1.4%	1,003	(7.6%)	2.0%	2.0%



# FY 2016 Developed & Emerging Markets

	Second Quarter			Year-to Date		
As Adjusted	\$	% of BD Revenues	Comparable FXN Growth %	\$	% of BD Revenues	Comparable FXN Growth %
Developed Markets	\$2,628	86%	5.3%	\$5,155	85%	3.5%
Emerging Markets	\$443	14%	5.1%	\$908	15%	3.7%
China	\$163	5%	9.4%	\$326	5%	6.9%



Note: Emerging markets include Eastern Europe, Middle East, Africa, Latin America, and certain countries within Asia Pacific. Emerging market revenue definition adjusted to exclude several countries within the Asia Pacific region: Australia, New Zealand, Korea, Singapore, Hong Kong, & Taiwan. A reconciliation is included in the appendix of this presentation.

# FY 2016 Safety Revenues

	Second Quarter				Year-to-Date			
	\$	Growth %	FXN Growth%	Comparable FXN Growth%	\$	Growth %	FXN Growth%	Comparable FXN Growth%
<b>Total Safety</b>	<b>\$733</b>	<b>33.2%</b>	<b>38.8%</b>	<b>6.7%</b>	<b>\$1,470</b>	<b>30.8%</b>	<b>37.0%</b>	<b>5.8%</b>
<b>By Geography</b>								
U.S.	443	50.7%	50.7%	4.5%	890	47.7%	47.7%	4.2%
International	290	13.1%	25.1%	9.9%	580	11.3%	24.6%	8.1%
<b>By Segment</b>								
Medical	465	65.5%	71.6%	8.0%	932	61.6%	68.0%	6.7%
Life Sciences	268	(0.5%)	4.6%	4.6%	538	(1.6%)	4.3%	4.3%

- Emerging Markets Safety grew 15.6% in Q2 and 13.2% Year-to-Date




# Q2 FY 2016 Adjusted Income Statement


	Favorable (Unfavorable)				
	Adjusted Q2 FY 2016	Adjusted Q2 FY 2015	\$ Change	% Change	FXN % Change
Revenues <b>Comparable basis</b>	\$3,071	\$2,051	\$1,020	49.7%	55.2% <b>5.3%</b>
Gross Profit	1,625	1,063	562	52.8%	58.8%
% of Revenues <b>Comparable basis</b>	52.9%	51.9% <b>51.4%</b>			<b>7.9%</b>
SSG&A	751	511	(240)	(46.9%)	(51.8%)
% of Revenues <b>Comparable basis</b>	24.5%	24.9% <b>26.1%</b>			<b>2.6%</b>
R&D	182	129	(52)	(40.4%)	(42.0%)
% of Revenues <b>Comparable basis</b>	5.9%	6.3% <b>6.0%</b>			<b>0.2%</b>
Operating Income	693	423	270	63.8%	72.4%
% of Revenues <b>Comparable basis</b>	22.6%	20.6% <b>19.2%</b>			<b>24.8%</b>
Tax Rate	20.6%	21.3%			
<b>Adjusted EPS</b>	<b>\$2.18</b>	<b>\$1.61</b>	<b>\$0.57</b>	<b>35.4%</b>	<b>44.7%</b>

# Q2 FY 2016 Adjusted Margin Changes Year-Over-Year

## Gross Profit (% of sales)



## Operating Margin (% of sales)



- ◆ Strong progress with ~290 bps underlying operating margin expansion through first half FY 2016



# Guidance


**Christopher Reidy**

Chief Financial Officer

Executive Vice President of Administration



# FY 2016 Adjusted EPS Guidance



**Raise Adjusted EPS Guidance Range to \$8.50 to \$8.57**



# FY 2016 Guidance

As Adjusted	February Guidance	May Update
<b>Total Revenues – FXN</b>	24.5% to 25.0%	24.5% to 25.0%
<b>Total Revenues – Rptd</b>	20.0% to 20.5%	<b>21.5% to 22.0%</b>
Medical Revenues – FXN	36.0% to 36.5%	36.0% to 36.5%
<b>Comparable Organic Total Revenues – FXN<sup>(1)</sup></b>	4.5% to 5.0%	4.5% to 5.0%
Comparable Medical Revenues – FXN <sup>(2)</sup>	4.5% to 5.0%	4.5% to 5.0%
Life Sciences Revenues – FXN	4.0% to 4.5%	4.0% to 4.5%
Gross Profit	52.0% to 52.5%	52.0% to 52.5%
SSG&A	24.0% to 24.5%	24.0% to 24.5%
R&D	6.0% to 6.5%	6.0% to 6.5%
Operating Income Underlying Margin Expansion <sup>(3)</sup>	21.0% to 22.0% +170 to 190 bps	21.0% to 22.0% +170 to 190 bps
Effective Tax Rate	21.0% to 22.0%	21.0% to 22.0%
<b>EPS</b>	\$8.37 to \$8.44	<b>\$8.50 to \$8.57</b>
<b>EPS – FXN</b>	\$9.01 to \$9.08	\$9.01 to \$9.08
<b>EPS – FXN Accretion</b>	~22% Accretion	~22% Accretion
<b>EPS – FXN Growth</b>	~26% to 27%	~26% to 27%
Operating Cash Flow	~\$2.6B	~\$2.6B
Capital Expenditures	~\$650-700M	~\$650-700M
Interest/Other, net	~(\$400M)	~(\$400M)
Share Count	~217M	~217M

Note: Guidance updates denoted in bold.



(1) Excludes the impact from a distribution agreement change in the Respiratory Solutions business, closed divestitures, and non-annualized acquisitions.

(2) Excludes the impact from a distribution agreement change in the Respiratory Solutions business.

(3) Underlying Margin Expansion excludes currency and pension impacts.

# Executive Overview

**Vincent A. Forlenza**

Chairman, CEO and President





# Q2 FY2016 Business Update: Growth and Strategic Initiatives

## New Product Innovation



- Two PAS new product launches:
  - BD UltraTouch™ Push Button Collection Set launched WW
  - BD Barricor™ launched x-US
- Positive uptake of FACSSymphony high-parameter instruments

## Strategic / Business Initiatives



- Completed strategic review:
  - Announced Respiratory Solutions joint venture
  - Sale of Spine business
- Over 50 CFN product registered in more than 20 countries

## Partnerships / Collaborations



- Launch of insulin infusion sets
- Strategic partnership with the Parker Institute for Cancer Immunotherapy




# Q2 FY2016 Business Update: Operational Efficiencies

## Operational Efficiencies



- G&A functional transformation continues:
  - Ongoing expansion of shared services
  - Harmonizing IT infrastructure and systems
- Remain on-track to achieve FY16 cost synergies

## Operating Margin Expansion (FXN)



Base plan efficiencies and synergies generating significant margin expansion



# Key Takeaways

- ◆ Solid Q2 results demonstrate portfolio diversity
- ◆ Great progress one-year post close of CareFusion acquisition
- ◆ Post-CFN strategic portfolio review completed
- ◆ Maintain currency-neutral revenue guidance
- ◆ Raise adjusted EPS guidance range

Advancing  
the World  
of Health



# Q2 FY 2016 & FY 2015 Adjustment Reconciliations

(Unaudited; Amounts in millions, except per share data)

Three Months Ended March 31, 2016												
	Revenues	Gross Profit	Selling and Administrative Expense	Research and Development Expense	Acquisitions and other restructurings	Operating Income	Interest Expense	Other Income, Net	Income Tax Provision	Net Income	Diluted Earnings per Share	
<b>Reported \$ for Three Months Ended March 31, 2016</b>	\$ 3,067	\$ 1,484	\$ 732	\$ 182	\$ 104	\$ 466	\$ (99)	\$ 6	\$ 38	\$ 338	\$ 1.56	
<i>Reported % of Revenues</i>		48.4%	23.9%	5.9%		15.2%				11.0%		
<i>Reported effective tax rate</i>									10.0%			
<b>Specified items:</b>												
Purchase accounting adjustments <sup>(1)</sup>	4	142	19	-	-	123	(8)	-	41	73	0.34	
Restructuring costs <sup>(2)</sup>	-	-	-	-	(64)	64	-	-	29	35	0.16	
Integration costs <sup>(2)</sup>	-	-	-	-	(40)	40	-	-	15	25	0.12	
<b>Adjusted \$ for Three Months Ended March 31, 2016</b>	<b>A \$ 3,071</b>	<b>\$ 1,625</b>	<b>\$ 751</b>	<b>\$ 182</b>	<b>\$ -</b>	<b>\$ 693</b>	<b>\$ (107)</b>	<b>\$ 6</b>	<b>\$ 122</b>	<b>\$ 472</b>	<b>\$ 2.18</b>	
<i>Adjusted % of Adjusted Revenues</i>		52.9%	24.5%	5.9%		22.6%				15.4%		
<i>Adjusted effective tax rate</i>									20.6%			
Three Months Ended March 31, 2015												
	Revenues	Gross Profit	Selling and Administrative Expense	Research and Development Expense	Acquisitions and other restructurings	Operating Income	Interest Expense	Other Income, Net	Income Tax Provision	Net Income	Diluted Earnings per Share	
<b>Reported \$ for Three Months Ended March 31, 2015</b>	\$ 2,051	\$ 1,046	\$ 511	\$ 129	\$ 113	\$ 293	\$ (91)	\$ 15	\$ 9	\$ 216	\$ 1.08	
<i>Reported % of Revenues</i>		51.0%	24.9%	6.3%		14.3%				10.6%		
<i>Reported effective tax rate</i>									3.9%			
<b>Specified items:</b>												
Purchase accounting adjustments <sup>(3)</sup>	-	18	-	-	-	18	-	(9)	6	3	0.01	
Restructuring costs <sup>(2)</sup>	-	-	-	-	(62)	62	-	-	26	36	0.18	
Integration costs <sup>(2)</sup>	-	-	-	-	(18)	18	-	-	7	10	0.05	
Transaction costs <sup>(2)</sup>	-	-	-	-	(33)	33	-	-	14	19	0.10	
Financing costs <sup>(2)</sup>	-	-	-	-	-	-	58	-	24	34	0.17	
Dilutive Share Impact <sup>(4)</sup>	-	-	-	-	-	-	-	-	-	-	0.02	
<b>Adjusted \$ for Three Months Ended March 31, 2015</b>	<b>B \$ 2,051</b>	<b>\$ 1,063</b>	<b>\$ 511</b>	<b>\$ 129</b>	<b>\$ -</b>	<b>\$ 423</b>	<b>\$ (33)</b>	<b>\$ 6</b>	<b>\$ 86</b>	<b>\$ 318</b>	<b>\$ 1.61</b>	
<i>Adjusted % of Revenues</i>		51.9%	24.9%	6.3%		20.6%				15.5%		
<i>Adjusted effective tax rate</i>									21.3%			
Three Months Ended March 31, 2016 versus March 31, 2015												
<b>Adjusted \$ change</b>	<b>C=A-B \$ 1,020</b>	<b>\$ 562</b>	<b>\$ (240)</b>	<b>\$ (52)</b>	<b>\$ -</b>	<b>\$ 270</b>	<b>\$ (74)</b>	<b>\$ (1)</b>	<b>\$ (36)</b>	<b>\$ 154</b>	<b>\$ 0.57</b>	
<b>Adjusted % change</b>	<b>D=C/B 49.7%</b>	<b>52.8%</b>	<b>(46.9%)</b>	<b>(40.4%)</b>	<b>-</b>	<b>63.8%</b>	<b>NM</b>	<b>(11.5%)</b>	<b>(42.1%)</b>	<b>48.2%</b>	<b>35.4%</b>	
<b>Foreign currency translation impact</b>	<b>E \$ (113)</b>	<b>\$ (63)</b>	<b>\$ 25</b>	<b>\$ 2</b>	<b>\$ -</b>	<b>\$ (36)</b>	<b>\$ -</b>	<b>\$ (4)</b>	<b>\$ 9</b>	<b>\$ (32)</b>	<b>\$ (0.15)</b>	
<b>Adjusted foreign currency neutral \$ change</b>	<b>F=C-E \$ 1,133</b>	<b>\$ 625</b>	<b>\$ (265)</b>	<b>\$ (54)</b>	<b>\$ -</b>	<b>\$ 306</b>	<b>\$ (74)</b>	<b>\$ 4</b>	<b>\$ (45)</b>	<b>\$ 186</b>	<b>\$ 0.72</b>	
<b>Adjusted foreign currency neutral % change</b>	<b>G=F/B 55.2%</b>	<b>58.8%</b>	<b>(51.8%)</b>	<b>(42.0%)</b>	<b>-</b>	<b>72.4%</b>	<b>NM</b>	<b>56.8%</b>	<b>(52.6%)</b>	<b>58.3%</b>	<b>44.7%</b>	

<sup>(1)</sup> Includes non-cash amortization expense of \$136 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of \$1 million pre-tax to reflect CareFusion's fixed assets, debt and deferred revenue balances at fair value as of the acquisition date. Also includes \$22 million of pre-tax income related to a net favorable change in the fair value of contingent consideration payments associated with certain acquisitions.

<sup>(2)</sup> Represents restructuring, integration, transaction and financing costs associated with the CareFusion acquisition and portfolio rationalization.

<sup>(3)</sup> Represents non-cash amortization expense associated with acquisition related identifiable intangible assets of \$18 million pre-tax, partially offset by an acquisition-date accounting gain of \$9 million pre-tax related to a previously held equity investment.

<sup>(4)</sup> Represents the dilutive impact of BD shares issued as part of purchase consideration for CareFusion acquisition prior to the consolidation of its operating results beginning on April 1, 2015. The quarter-to-date adjusted diluted average shares outstanding (in thousands) is 197,436.

NM - Not Meaningful



# Q2 YTD FY 2016 & FY 2015 Adjustment Reconciliations

(Unaudited; Amounts in millions, except per share data)

Six Months Ended March 31, 2016												
	Revenues	Gross Profit	Selling and Administrative Expense	Research and Development Expense	Acquisitions and other restructurings	Operating Income	Interest Expense	Other Income, Net	Income Tax Provision	Net Income	Diluted Earnings per Share	
<b>Reported \$ for Six Months Ended March 31, 2016</b>	\$ 6,054	\$ 2,892	\$ 1,480	\$ 369	\$ 225	\$ 818	\$ (196)	\$ 11	\$ 75	\$ 567	\$ 2.62	
<i>Reported % of Revenues</i>		47.8%	24.5%	6.1%		13.5%				9.4%		
<i>Reported effective tax rate</i>									11.7%			
<b>Specified items:</b>												
Purchase accounting adjustments <sup>(1)</sup>	9	300	16	-	-	284	(16)	-	75	193	0.89	
Restructuring costs <sup>(2)</sup>	-	-	-	-	(149)	149	-	-	61	89	0.41	
Integration costs <sup>(2)</sup>	-	-	-	-	(75)	75	-	-	28	47	0.22	
<b>Adjusted \$ for Six Months Ended March 31, 2016</b>	<b>A \$ 6,063</b>	<b>\$ 3,191</b>	<b>\$ 1,496</b>	<b>\$ 369</b>	<b>\$ -</b>	<b>\$ 1,326</b>	<b>\$ (212)</b>	<b>\$ 11</b>	<b>\$ 239</b>	<b>\$ 896</b>	<b>\$ 4.13</b>	
<i>Adjusted % of Adjusted Revenues</i>		52.6%	24.7%	6.1%		21.9%				14.8%		
<i>Adjusted effective tax rate</i>									21.0%			
Six Months Ended March 31, 2015												
	Revenues	Gross Profit	Selling and Administrative Expense	Research and Development Expense	Acquisitions and other restructurings	Operating Income	Interest Expense	Other Income, Net	Income Tax Provision	Net Income	Diluted Earnings per Share	
<b>Reported \$ for Six Months Ended March 31, 2015</b>	\$ 4,102	\$ 2,091	\$ 1,055	\$ 258	\$ 136	\$ 642	\$ (167)	\$ 17	\$ 58	\$ 452	\$ 2.28	
<i>Reported % of Revenues</i>		51.0%	25.7%	6.3%		15.6%				11.0%		
<i>Reported effective tax rate</i>									11.4%			
<b>Specified items:</b>												
Purchase accounting adjustments <sup>(3)</sup>	-	35	-	-	-	35	-	(9)	12	15	0.08	
Restructuring costs <sup>(2)</sup>	-	-	-	-	(62)	62	-	-	26	36	0.18	
Integration costs <sup>(2)</sup>	-	-	-	-	(31)	31	-	-	12	19	0.10	
Transaction costs <sup>(2)</sup>	-	-	-	-	(43)	43	-	-	14	29	0.15	
Financing costs <sup>(2)</sup>	-	-	-	-	-	-	102	-	40	62	0.31	
Litigation-related Charge <sup>(4)</sup>	-	-	(12)	-	-	12	-	-	4	7	0.04	
Dilutive Share Impact <sup>(5)</sup>	-	-	-	-	-	-	-	-	-	-	0.02	
<b>Adjusted \$ for Six Months Ended March 31, 2015</b>	<b>B \$ 4,102</b>	<b>\$ 2,127</b>	<b>\$ 1,043</b>	<b>\$ 258</b>	<b>\$ -</b>	<b>\$ 825</b>	<b>\$ (65)</b>	<b>\$ 9</b>	<b>\$ 167</b>	<b>\$ 621</b>	<b>\$ 3.14</b>	
<i>Adjusted % of Revenues</i>		51.8%	25.4%	6.3%		20.1%				15.1%		
<i>Adjusted effective tax rate</i>									21.2%			
Six Months Ended March 31, 2016 versus March 31, 2015												
<b>Adjusted \$ change</b>	<b>C=A-B \$ 1,961</b>	<b>\$ 1,065</b>	<b>\$ (453)</b>	<b>\$ (110)</b>	<b>\$ -</b>	<b>\$ 501</b>	<b>\$ (147)</b>	<b>\$ 3</b>	<b>\$ (72)</b>	<b>\$ 275</b>	<b>\$ 0.99</b>	
<b>Adjusted % change</b>	<b>D=C/B 47.8%</b>	<b>50.1%</b>	<b>(43.4%)</b>	<b>(42.8%)</b>	<b>-</b>	<b>60.8%</b>	<b>NM</b>	<b>31.5%</b>	<b>(43.3%)</b>	<b>44.4%</b>	<b>31.5%</b>	
<b>Foreign currency translation impact</b>	<b>E \$ (275)</b>	<b>\$ (176)</b>	<b>\$ 64</b>	<b>\$ 5</b>	<b>\$ -</b>	<b>\$ (107)</b>	<b>\$ -</b>	<b>\$ (8)</b>	<b>\$ 26</b>	<b>\$ (90)</b>	<b>\$ (0.42)</b>	
<b>Adjusted foreign currency neutral \$ change</b>	<b>F=C-E \$ 2,236</b>	<b>\$ 1,241</b>	<b>\$ (517)</b>	<b>\$ (116)</b>	<b>\$ -</b>	<b>\$ 609</b>	<b>\$ (147)</b>	<b>\$ 11</b>	<b>\$ (98)</b>	<b>\$ 365</b>	<b>\$ 1.41</b>	
<b>Adjusted foreign currency neutral % change</b>	<b>G=F/B 54.5%</b>	<b>58.4%</b>	<b>(49.5%)</b>	<b>(44.8%)</b>	<b>-</b>	<b>73.8%</b>	<b>NM</b>	<b>NM</b>	<b>(58.6%)</b>	<b>58.9%</b>	<b>44.9%</b>	

<sup>(1)</sup> Includes non-cash amortization expense of \$285 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of \$5 million pre-tax to reflect CareFusion's fixed assets, debt and deferred revenue balances at fair value as of the acquisition date. Also includes \$22 million of pre-tax income related to a net favorable change in the fair value of contingent consideration payments associated with certain acquisitions.

<sup>(2)</sup> Represents restructuring, integration, transaction and financing costs associated with the CareFusion acquisition and portfolio rationalization.

<sup>(3)</sup> Represents non-cash amortization expense associated with acquisition related identifiable intangible assets of \$35 million pre-tax, partially offset by an acquisition-date accounting gain of \$9 million pre-tax related to a previously held equity investment.

<sup>(4)</sup> Represents a charge for plaintiffs' attorneys' fees associated with the unfavorable verdict in the antitrust and false advertising lawsuit filed against BD by RTI.

<sup>(5)</sup> Represents the dilutive impact of BD shares issued as part of purchase consideration for CareFusion acquisition prior to the consolidation of its operating results beginning on April 1, 2015. The year-to-date adjusted diluted average shares outstanding (in thousands) is 197,390.

NM - Not Meaningful



# Q2 FY 2016 Reconciliation of Reported Diluted EPS to Adjusted Diluted EPS

(Unaudited)

	Three Months Ended March 31,						
	2016	2015	Growth	Foreign Currency Translation	Foreign Currency Neutral Growth	Growth %	Foreign Currency Neutral Growth %
Reported Diluted Earnings per Share	\$ 1.56	\$ 1.08	\$ 0.48	\$ (0.14)	\$ 0.62	44.4%	57.4%
Purchase Accounting Adjustments (\$115 million or \$73 million after-tax and \$9 million or \$3 million after-tax, respectively)	0.34 <sup>(1)</sup>	0.01 <sup>(2)</sup>					
Restructuring Costs (\$64 million or \$35 million after-tax and \$62 million or \$36 million after-tax, respectively) <sup>(3)</sup>	0.16	0.18					
Integration Costs (\$40 million or \$25 million after-tax and \$18 million or \$10 million after-tax, respectively) <sup>(3)</sup>	0.12	0.05					
Transaction Costs (\$33 million or \$19 million after-tax) <sup>(3)</sup>	-	0.10					
Financing Costs (\$58 million or \$34 million after-tax) <sup>(3)</sup>	-	0.17					
Dilutive Share Impact <sup>(4)</sup>	-	0.02					
Adjusted Diluted Earnings per Share	\$ 2.18	\$ 1.61	\$ 0.57	\$ (0.15)	\$ 0.72	35.4%	44.7%

<sup>(1)</sup> Includes non-cash amortization expense of \$136 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of \$1 million pre-tax to reflect CareFusion's fixed assets, debt and deferred revenue balances at fair value as of the acquisition date. Also includes \$22 million of pre-tax income related to a net favorable change in the fair value of contingent consideration payments associated with certain acquisitions.

<sup>(2)</sup> Represents non-cash amortization expense associated with acquisition related identifiable intangible assets of \$18 million pre-tax, partially offset by an acquisition-date accounting gain of \$9 million pre-tax related to a previously held equity investment.

<sup>(3)</sup> Represents restructuring, integration, transaction and financing costs associated with the CareFusion acquisition and portfolio rationalization.

<sup>(4)</sup> Represents the dilutive impact of BD shares issued as part of purchase consideration for CareFusion acquisition prior to the consolidation of its operating results beginning on April 1, 2015. The quarter-to-date adjusted diluted average shares outstanding (in thousands) is 197,436.



# Q2 YTD 2016 Reconciliation of Reported Diluted EPS to Adjusted Diluted EPS

(Unaudited)

	Six Months Ended March 31,						
	2016	2015	Growth	Foreign Currency Translation	Foreign Currency Neutral Growth	Growth %	Foreign Currency Neutral Growth %
Reported Diluted Earnings per Share	\$ 2.62	\$ 2.28	\$ 0.34	\$ (0.40)	\$ 0.74	14.9%	32.5%
Purchase Accounting Adjustments (\$268 million or \$193 million after-tax and \$27 million or \$15 million after-tax, respectively)	0.89 <sup>(1)</sup>	0.08 <sup>(2)</sup>					
Restructuring Costs (\$149 million or \$89 million after-tax and \$62 million or \$36 million after-tax, respectively) <sup>(3)</sup>	0.41	0.18		(0.01)			
Integration Costs (\$75 million or \$47 million after-tax and \$31 million or \$19 million after-tax, respectively) <sup>(3)</sup>	0.22	0.10					
Transaction Costs (\$43 million or \$29 million after-tax) <sup>(3)</sup>	-	0.15					
Financing Costs (\$102 million or \$62 million after-tax) <sup>(3)</sup>	-	0.31					
Litigation-related Charge (\$12 million or \$7 million after-tax) <sup>(4)</sup>	-	0.04					
Dilutive Share Impact <sup>(5)</sup>	-	0.02					
Adjusted Diluted Earnings per Share	\$ 4.13	\$ 3.14	\$ 0.99	\$ (0.42)	\$ 1.41	31.5%	44.9%

<sup>(1)</sup> Includes non-cash amortization expense of \$285 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of \$5 million pre-tax to reflect CareFusion's fixed assets, debt and deferred revenue balances at fair value as of the acquisition date. Also includes \$22 million of pre-tax income related to a net favorable change in the fair value of contingent consideration payments associated with certain acquisitions.

<sup>(2)</sup> Represents non-cash amortization expense associated with acquisition related identifiable intangible assets of \$35 million pre-tax, partially offset by an acquisition-date accounting gain of \$9 million pre-tax related to a previously held equity investment.

<sup>(3)</sup> Represents restructuring, integration, transaction and financing costs associated with the CareFusion acquisition and portfolio rationalization.

<sup>(4)</sup> Represents a charge for plaintiff's attorneys' fees associated with the unfavorable verdict in the antitrust and false advertising lawsuit filed against BD by RTI.

<sup>(5)</sup> Represents the dilutive impact of BD shares issued as part of purchase consideration for CareFusion acquisition prior to the consolidation of its operating results beginning on April 1, 2015. The year-to-date adjusted diluted average shares outstanding (in thousands) is 197,390.





# FY 2016 Reconciliation – FX Impact Emerging and Developed Markets

(Unaudited; Amounts in millions)

	Emerging Markets						Developed Markets					
	Q1	Q2	Q2 YTD	Q3	Q4	Full Year	Q1	Q2	Q2 YTD	Q3	Q4	Full Year
BDX Reported 2016	465	443	908				2,527	2,628	5,155			
<i>Adjusted Comparable Growth %</i>	(8.7)	(5.2)	(7.0)				(2.4)	2.8	0.2			
<i>FX Neutral Growth %</i>	2.4	5.1	3.7				1.7	5.3	3.5			
<i>FX Impact %</i>	(11.2)	(10.3)	(10.8)				(4.1)	(2.5)	(3.3)			
A BD Legacy Reported 2015 (Old Definition)	543	516	1,059	539	545	2,143	1,509	1,535	3,044	1,530	1,589	6,162
<i>Adjusted Reported Growth %</i>	7.9	1.6	4.8	1.6	(6.3)	0.9	(0.2)	(1.9)	(1.1)	(5.9)	(2.0)	(2.5)
<i>FX Neutral Growth %</i>	12.4	7.6	10.0	11.0	5.9	9.2	2.9	4.0	3.5	2.6	5.4	3.7
<i>FX Impact %</i>	(4.5)	(6.1)	(5.3)	(9.4)	(12.3)	(8.2)	(3.2)	(5.9)	(4.6)	(8.5)	(7.3)	(6.3)
B BD Legacy Adjustment 2015 *	(92)	(87)	(180)	(96)	(93)	(368)	92	87	180	96	93	368
A+B=C BD Legacy As Adjusted 2015 (New Definition)	451	428	879	443	452	1,775	1,601	1,622	3,223	1,626	1,681	6,530
<i>Adjusted Reported Growth %</i>	10.2	2.2	6.2	1.0	(5.3)	1.7	(0.3)	(1.8)	(1.1)	(5.4)	(2.5)	(2.5)
<i>FX Neutral Growth %</i>	14.6	8.3	11.4	10.4	6.7	9.9	2.9	4.1	3.5	3.2	5.2	3.9
<i>FX Impact %</i>	(4.5)	(6.1)	(5.3)	(9.4)	(12.0)	(8.2)	(3.2)	(5.9)	(4.6)	(8.6)	(7.7)	(6.4)
D CFN Legacy Reported 2015 (New Definition)	59	38	98	48	37	182	1,010	959	1,968	1,016	897	3,881
E Respiratory Adjustment **	-	-	-	-	-	-	(23)	(23)	(46)	(25)	(7)	(78)
C+D+E Comparable Historical 2015	510	467	977	491	489	1,957	2,588	2,558	5,146	2,617	2,571	10,334
<i>Adjusted Comparable Growth %</i>	11.5	(0.0)	5.7	(0.5)	(6.1)	0.9	5.3	0.3	2.8	(5.2)	(1.0)	(0.3)
<i>FX Neutral Growth %</i>	15.7	5.8	10.7	8.7	5.3	8.8	7.9	4.9	6.4	1.2	5.0	4.7
<i>FX Impact %</i>	(4.2)	(5.9)	(5.1)	(9.2)	(11.4)	(7.8)	(2.6)	(4.6)	(3.6)	(6.4)	(6.0)	(5.0)

\* Emerging markets include Eastern Europe, Middle East, Africa, Latin America, and certain countries within Asia Pacific. Emerging market revenue definition adjusted to exclude several countries within the Asia Pacific region: Australia, New Zealand, Korea, Singapore, Hong Kong, & Taiwan.

\*\* To reflect the impact of a distribution agreement change in the Respiratory Solutions unit that occurred toward the end of fiscal 2015, as if it had occurred as of October 1, 2014.



# FY 2016 Reconciliation – FX Impact Emerging Markets Safety and China

(Unaudited; Amounts in millions)

		Emerging Markets Safety					
		Q1	Q2	Q2 YTD	Q3	Q4	Full Year
BDX Reported 2016		100	104	204			
<i>Adjusted Comparable Growth %</i>		(3.6)	2.9	(0.4)			
<i>FX Neutral Growth %</i>		10.9	15.6	13.2			
<i>FX Impact %</i>		(14.4)	(12.7)	(13.6)			
A	BD Legacy Reported 2015 (Old Definition)	122	113	235	123	122	480
B	BD Adjustment 2015 *	(23)	(21)	(44)	(22)	(22)	(88)
A+B=C	BD Legacy As Adjusted 2015 (New Definition)	99	92	191	101	100	392
D	CFN Legacy Reported 2015 (New Definition)	5	9	14	8	9	32
C+D	Comparable Historical 2015	104	101	205	109	110	424

\* Emerging markets include Eastern Europe, Middle East, Africa, Latin America, and certain countries within Asia Pacific. Emerging market revenue definition adjusted to exclude several countries within the Asia Pacific region: Australia, New Zealand, Korea, Singapore, Hong Kong, & Taiwan.

		China					
		Q1	Q2	Q2 YTD	Q3	Q4	Full Year
BDX Reported 2016		163	163	326			
<i>Adjusted Comparable Growth %</i>		1.1	5.1	3.1			
<i>FX Neutral Growth %</i>		4.5	9.4	6.9			
<i>FX Impact %</i>		(3.3)	(4.3)	(3.8)			
A	BD Legacy Reported 2015	152	150	302	153	142	597
	<i>Adjusted Reported Growth %</i>	22.7	12.9	17.6	15.7	7.2	14.5
	<i>FX Neutral Growth %</i>	23.1	15.1	19.0	15.4	8.5	15.4
	<i>FX Impact %</i>	(0.4)	(2.2)	(1.3)	0.3	(1.3)	(0.9)
B	CFN Legacy Reported 2015	9	6	14	8	7	29
A+B	Comparable Historical 2015	161	155	317	161	149	627
	<i>Adjusted Comparable Growth %</i>	21.6	11.7	16.5	13.7	6.9	13.4
	<i>FX Neutral Growth %</i>	22.2	14.1	18.1	13.9	8.4	14.6
	<i>FX Impact %</i>	(0.6)	(2.5)	(1.6)	(0.2)	(1.5)	(1.2)



# Q2 FY 2016 Comparable Margin Reconciliation

(Unaudited; Amounts in millions)

Three Months Ended March 31, 2016						
		Revenues	Gross Profit	Selling and Administrative Expense	Research and Development Expense	Operating Income
<b>Adjusted \$ for Three Months Ended March 31, 2016</b>	<b>A</b>	<b>\$ 3,071</b>	<b>\$ 1,625</b>	<b>\$ 751</b>	<b>\$ 182</b>	<b>\$ 693</b>
<i>Adjusted % of Adjusted Revenues</i>			52.9%	24.5%	5.9%	22.6%
Three Months Ended March 31, 2015						
		Revenues	Gross Profit	Selling and Administrative Expense	Research and Development Expense	Operating Income
<b>BD Standalone for Three Months Ended March 31, 2015</b>		<b>\$ 2,051</b>	<b>\$ 1,046</b>	<b>\$ 511</b>	<b>\$ 129</b>	<b>\$ 293</b>
<i>Reported % of Revenues</i>			51.0%	24.9%	6.3%	14.3%
<b>Specified items:</b>						
Purchase accounting adjustments <sup>(1)</sup>		-	18	-	-	18
Restructuring costs <sup>(2)</sup>		-	-	-	-	62
Integration costs <sup>(2)</sup>		-	-	-	-	18
Transaction costs <sup>(2)</sup>		-	-	-	-	33
<b>BD Standalone Adjusted for Three Months Ended March 31, 2015</b>	<b>B</b>	<b>\$ 2,051</b>	<b>\$ 1,063</b>	<b>\$ 511</b>	<b>\$ 129</b>	<b>\$ 423</b>
<i>Adjusted % of Reported Revenues</i>			51.9%	24.9%	6.3%	20.6%
<b>CareFusion Reported for Three Months Ended March 31, 2015</b>		<b>\$ 997</b>	<b>\$ 440</b>	<b>\$ 279</b>	<b>\$ 54</b>	<b>\$ (23)</b>
<i>Reported % of Revenues</i>			44.1%	28.0%	5.4%	-2.3%
<b>Specified items:</b>						
Restructuring and acquisition integration <sup>(3)</sup>		-	-	-	-	133
Amortization of acquired intangibles <sup>(4)</sup>		-	-	(18)	-	18
P&L line reclassifications <sup>(5)</sup>		-	25	24	1	(2)
Respiratory adjustment <sup>(6)</sup>		(23)	-	-	-	-
Respiratory product recall adjustment <sup>(7)</sup>		-	36	-	-	36
<b>CareFusion Adjusted for Three Months Ended March 31, 2015</b>	<b>C</b>	<b>\$ 974</b>	<b>\$ 502</b>	<b>\$ 285</b>	<b>\$ 55</b>	<b>\$ 161</b>
<i>Adjusted % of Reported Revenues</i>			50.3%	28.6%	5.5%	16.2%
<b>Comparable Adjusted for Three Months Ended March 31, 2015</b>	<b>D=B+C</b>	<b>\$ 3,025</b>	<b>\$ 1,565</b>	<b>\$ 797</b>	<b>\$ 184</b>	<b>\$ 584</b>
<i>Adjusted % of Reported Revenues</i>			51.4%	26.1%	6.0%	19.2%
Three Months Ended March 31, 2016 versus March 31, 2015						
<b>Comparable adjusted \$ change</b>	<b>E=A-D</b>	<b>\$ 46</b>	<b>\$ 60</b>	<b>\$ 46</b>	<b>\$ 2</b>	<b>\$ 108</b>
<b>Comparable adjusted % change</b>	<b>F=E/D</b>	<b>1.5%</b>	<b>3.8%</b>	<b>5.7%</b>	<b>1.4%</b>	<b>18.5%</b>
<b>Comparable foreign currency translation impact</b>	<b>G</b>	<b>\$ (113)</b>	<b>\$ (63)</b>	<b>\$ 25</b>	<b>\$ 2</b>	<b>\$ (36)</b>
<b>Comparable adjusted foreign currency neutral \$ change</b>	<b>H=E-G</b>	<b>\$ 159</b>	<b>\$ 124</b>	<b>\$ 21</b>	<b>\$ -</b>	<b>\$ 145</b>
<b>Comparable adjusted foreign currency neutral % change</b>	<b>I=H/D</b>	<b>5.3%</b>	<b>7.9%</b>	<b>2.6%</b>	<b>0.2%</b>	<b>24.8%</b>

<sup>(1)</sup> Represents non-cash amortization expense associated with acquisition related identifiable intangible assets.

<sup>(2)</sup> Represents restructuring, integration and transaction costs associated with the CareFusion acquisition.

<sup>(3)</sup> Represents restructuring and acquisition integration charges primarily related to transaction costs, integration planning expenses and other charges associated with the company's proposed merger with Becton, Dickinson and Company, as provided by CareFusion management.

<sup>(4)</sup> Represents non-cash expense associated with amortization of identifiable intangible assets of acquired businesses, as provided by CareFusion management.

<sup>(5)</sup> Represents the reclassification of CareFusion P&L line items to align with BD.

<sup>(6)</sup> Represents the impact of a distribution agreement change in the Respiratory Solutions unit that occurred toward the end of fiscal 2015, as if it had occurred as of October 1, 2014.

<sup>(7)</sup> Represents AVEA product recall expenses incurred by the Respiratory Solutions unit.



# Q2 YTD FY 2016 Comparable Margin Reconciliation

(Unaudited; Amounts in millions)

Six Months Ended March 31, 2016						
	Revenues	Gross Profit	Selling and Administrative Expense	Research and Development Expense	Operating Income	
<b>Adjusted \$ for Six Months Ended March 31, 2016</b>	<b>\$ 6,063</b>	<b>\$ 3,191</b>	<b>\$ 1,496</b>	<b>\$ 369</b>	<b>\$ 1,326</b>	
<i>Adjusted % of Adjusted Revenues</i>		52.6%	24.7%	6.1%	21.9%	
<b>Six Months Ended March 31, 2015</b>						
	Revenues	Gross Profit	Selling and Administrative Expense	Research and Development Expense	Operating Income	
<b>BD Standalone for Six Months Ended March 31, 2015</b>	<b>\$ 4,102</b>	<b>\$ 2,091</b>	<b>\$ 1,055</b>	<b>\$ 258</b>	<b>\$ 642</b>	
<i>Reported % of Revenues</i>		51.0%	25.7%	6.3%	15.6%	
<b>Specified items:</b>						
Purchase accounting adjustments <sup>(1)</sup>	-	35	-	-	35	
Restructuring costs <sup>(2)</sup>	-	-	-	-	62	
Integration costs <sup>(2)</sup>	-	-	-	-	31	
Transaction costs <sup>(2)</sup>	-	-	-	-	43	
Litigation-related Charge <sup>(3)</sup>	-	-	(12)	-	12	
<b>BD Standalone Adjusted for Six Months Ended March 31, 2015</b>	<b>\$ 4,102</b>	<b>\$ 2,127</b>	<b>\$ 1,043</b>	<b>\$ 258</b>	<b>\$ 825</b>	
<i>Adjusted % of Reported Revenues</i>		51.8%	25.4%	6.3%	20.1%	
<b>CareFusion Reported for Six Months Ended March 31, 2015</b>	<b>\$ 2,066</b>	<b>\$ 975</b>	<b>\$ 557</b>	<b>\$ 103</b>	<b>\$ 155</b>	
<i>Reported % of Revenues</i>		47.2%	27.0%	5.0%	7.5%	
<b>Specified items:</b>						
Restructuring and acquisition integration <sup>(4)</sup>	-	-	-	-	165	
Amortization of acquired intangibles <sup>(5)</sup>	-	-	(37)	-	37	
P&L line reclassifications <sup>(6)</sup>	-	48	46	2	(4)	
Respiratory adjustment <sup>(7)</sup>	(46)	-	-	-	-	
Respiratory product recall adjustment <sup>(8)</sup>	-	36	-	-	36	
<b>CareFusion Adjusted for Six Months Ended March 31, 2015</b>	<b>\$ 2,020</b>	<b>\$ 1,059</b>	<b>\$ 566</b>	<b>\$ 105</b>	<b>\$ 388</b>	
<i>Adjusted % of Reported Revenues</i>		51.3%	27.4%	5.1%	18.8%	
<b>Comparable Adjusted for Six Months Ended March 31, 2015</b>	<b>\$ 6,122</b>	<b>\$ 3,186</b>	<b>\$ 1,609</b>	<b>\$ 363</b>	<b>\$ 1,213</b>	
<i>Adjusted % of Reported Revenues</i>		51.6%	26.1%	5.9%	19.7%	
<b>Six Months Ended March 31, 2016 versus March 31, 2015</b>						
<b>Comparable adjusted \$ change</b>	<b>E=A-D</b>	<b>\$ (59)</b>	<b>\$ 6</b>	<b>\$ 113</b>	<b>\$ (5)</b>	<b>\$ 113</b>
<b>Comparable adjusted % change</b>	<b>F=E/D</b>	<b>(1.0%)</b>	<b>0.2%</b>	<b>7.0%</b>	<b>(1.5%)</b>	<b>9.3%</b>
<b>Comparable foreign currency translation impact</b>	<b>G</b>	<b>\$ (275)</b>	<b>\$ (176)</b>	<b>\$ 64</b>	<b>\$ 5</b>	<b>\$ (107)</b>
<b>Comparable adjusted foreign currency neutral \$ change</b>	<b>H=E-G</b>	<b>\$ 216</b>	<b>\$ 182</b>	<b>\$ 49</b>	<b>\$ (11)</b>	<b>\$ 220</b>
<b>Comparable adjusted foreign currency neutral % change</b>	<b>I=H/D</b>	<b>3.5%</b>	<b>5.7%</b>	<b>3.1%</b>	<b>(2.9%)</b>	<b>18.2%</b>

<sup>(1)</sup> Represents non-cash amortization expense associated with acquisition related identifiable intangible assets.

<sup>(2)</sup> Represents restructuring, integration and transaction costs associated with the CareFusion acquisition.

<sup>(3)</sup> Represents a charge for plaintiff's attorneys' fees associated with the unfavorable verdict in the antitrust and false advertising lawsuit filed against BD by RTI.

<sup>(4)</sup> Represents restructuring and acquisition integration charges primarily related to transaction costs, integration planning expenses and other charges associated with the company's proposed merger with Becton, Dickinson and Company, as provided by CareFusion management.

<sup>(5)</sup> Represents non-cash expense associated with amortization of identifiable intangible assets of acquired businesses, as provided by CareFusion management.

<sup>(6)</sup> Represents the reclassification of CareFusion P&L line items to align with BD.

<sup>(7)</sup> Represents the impact of a distribution agreement change in the Respiratory Solutions unit that occurred toward the end of fiscal 2015, as if it had occurred as of October 1, 2014.

<sup>(8)</sup> Represents AVEA product recall expenses incurred by the Respiratory Solutions unit.



# FY 2016 Outlook Reconciliation

	FY2015		FY2016 Outlook	
	Revenues	% Increase	FX Impact	% Increase FXN
BDX As Reported Revenue	\$ 10,282	21.5% - 22.0%	~(3.0%)	24.5% - 25.0%
Deferred Revenue Adjustment	20	NM	NM	NM
BDX As Adjusted Revenue	10,302	21.5% - 22.0%	~(3.0%)	24.5% - 25.0%
CareFusion First Half Revenue	2,066			
Respiratory Solution Adjustment <sup>(1)</sup>	(78)			
				<u>% Increase FXN</u>
				<u>Comparable</u>
BDX Comparable Revenue	12,290	4.5% - 5.0%		
				<u>Comparable</u>
				<u>Organic</u>
Inorganic Revenue <sup>(2)</sup>	(27)			
BDX Comparable Organic Revenue	<u>\$ 12,263</u>	4.5% - 5.0%		
				<u>% Increase FXN</u>
				<u>Comparable</u>
BD Medical Revenue	\$ 6,460			
Deferred Revenue Adjustment	20			
BD Medical As Adjusted Revenue	6,480			
CareFusion First Half Revenue	2,066			
Respiratory Solution Adjustment <sup>(1)</sup>	(78)			
				<u>% Increase FXN</u>
				<u>Comparable</u>
BD Medical Comparable Revenue	<u>\$ 8,469</u>	4.5% - 5.0%		

	FY2015		FY2016 Outlook	
	Operating Income	Operating Margin (% of Sales)		
BDX Adjusted Operating Income	\$ 2,177	21.1%		
CareFusion First Half Operating Income	388	NM		
BDX Comparable Adjusted Operating Income	<u>\$ 2,566</u>	20.7%	~21.0% - 22.0%	

	FY2016 Outlook		% Increase
	Full Year FY2016 (estimated)	Full Year FY2015	
Reported Fully Diluted Earnings per Share	\$ 6.14 - 6.21	\$ 3.35	NM
Purchase Accounting Adjustments	1.73	2.17	
Restructuring Costs	0.41 <sup>(3)</sup>	0.80	
Integration Costs	0.22 <sup>(3)</sup>	0.29	
Transaction Costs	-	0.19	
Financing Costs	-	0.31	
Litigation-related Charge	-	0.04	
Employee Termination Cost-related Amounts	-	(0.01)	
Dilutive Share Impact	-	0.02	
Adjusted Fully Diluted Earnings per Share	<u>\$ 8.50 - 8.57</u>	<u>\$ 7.16</u>	19.0% - 20.0%
FX Impact	<u>\$ (0.51)</u>		~(7.0%)
Adjusted FXN Growth	<u>\$ 9.01 - 9.08</u>		26.0% - 27.0%

<sup>(1)</sup> To reflect the impact of a distribution agreement change in the Respiratory Solutions unit that occurred toward the end of fiscal 2015, as if it had occurred as of October 1, 2014.

<sup>(2)</sup> Adjusts FY2015 revenues for the following closed divestitures: Simplist and Spine.

<sup>(3)</sup> FY2016 restructuring and integration cost reflect year-to-date realized costs.

NM - Not Meaningful

FXN - Foreign Currency Neutral



# FY 2016+ Product Launches

Medical Segment Program / Product	Planned Launch Date
<ul style="list-style-type: none"> <li>• BD Insulin Infusion Sets</li> <li>• Pyxis Mini</li> </ul>	<ul style="list-style-type: none"> <li>➤ FY 2016</li> <li>➤ FY 2016</li> </ul>
Life Sciences Segment Program / Product	Planned Launch Date
<ul style="list-style-type: none"> <li>• BD MAX™ – Extended Enteric Bacterial</li> <li>• BD MAX™ – Enteric Viral</li> <li>• BD MAX™ – GC/CT and GC/CT/Trich</li> <li>• BD MAX™ – Vaginitis / Vaginosis</li>   <li>• BD Veritor™ – Next Generation</li> <li>• BD Totalys™</li>   <li>• BD Horizon™ (Sirigen) Dyes</li> <li>• BD FACSCelesta</li> <li>• BD FACSseq</li> <li>• BD Clic LP</li> <li>• BD Barricor™</li> <li>• BD UltraTouch™ PBBCS</li> </ul>	<ul style="list-style-type: none"> <li>➤ FY 2016 EU / FY 2017 U.S.</li> <li>➤ FY 2017 EU / FY 2017 U.S.</li> <li>➤ FY 2016 U.S.</li> <li>✔ FY 2016 EU clearance; ➤ FY 2016 U.S. Launch</li> <li>➤ FY 2016</li> <li>✔ Q2 FDA Clearance; ➤ FY 2016 U.S. Launch</li> <li>✔ Q1 FY 2016</li> <li>✔ 1H FY 2016</li> <li>➤ FY 2016</li> <li>➤ FY 2016</li> <li>✔ Launched x-U.S.; FY 2016 U.S.</li> <li>✔ FY 2016</li> </ul>

